Cargando…

MicroRNA-138-5p Suppresses Non-small Cell Lung Cancer Cells by Targeting PD-L1/PD-1 to Regulate Tumor Microenvironment

Non-small cell lung cancer (NSCLC) is still challenging for treatment owing to immune tolerance and evasion. MicroRNA-138 (miR-138) not only acts as a tumor suppressor to inhibit tumor cell proliferation and migration but also regulates immune response. The regulatory mechanism of miR-138 in NSCLC r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Nannan, Li, Peng, Song, Pingping, Li, Yintao, Zhou, Shuping, Su, Qinghong, Li, Xiaofan, Yu, Yong, Li, Pengfei, Feng, Meng, Zhang, Min, Lin, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Cell and Developmental Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365935/ https://www.ncbi.nlm.nih.gov/pubmed/32754587 http://dx.doi.org/10.3389/fcell.2020.00540

Ejemplares similares

Corrigendum: MicroRNA-138-5p Suppresses Non-small Cell Lung Cancer Cells by Targeting PD-L1/PD-1 to Regulate Tumor Microenvironment
por: Song, Nannan, et al.
Publicado: (2020)

Soluble CD83 Regulates Dendritic Cell–T Cell Immunological Synapse Formation by Disrupting Rab1a-Mediated F-Actin Rearrangement
por: Lin, Wei, et al.
Publicado: (2021)

Regulation of the Migration of Distinct Dendritic Cell Subsets
por: Feng, Meng, et al.
Publicado: (2021)

Comprehensive Analysis of Ferroptosis Regulators With Regard to PD-L1 and Immune Infiltration in Clear Cell Renal Cell Carcinoma
por: Wang, Song, et al.
Publicado: (2021)

Immunity-Related Gene Signature Identifies Subtypes Benefitting From Adjuvant Chemotherapy or Potentially Responding to PD1/PD-L1 Blockage in Pancreatic Cancer
por: Qian, Hao, et al.
Publicado: (2021)

Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv
por: Ping, Yu, et al.
Publicado: (2020)

Differential Role of PD-1 Expressed by Various Immune and Tumor Cells in the Tumor Immune Microenvironment: Expression, Function, Therapeutic Efficacy, and Resistance to Cancer Immunotherapy
por: Kim, Myeong Joon, et al.
Publicado: (2021)

Exosomal miRNA-16-5p Derived From M1 Macrophages Enhances T Cell-Dependent Immune Response by Regulating PD-L1 in Gastric Cancer
por: Li, Zhengtian, et al.
Publicado: (2020)

Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma
por: Fu, Yuyin, et al.
Publicado: (2021)

A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma
por: Song, Congkuan, et al.
Publicado: (2021)

Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
por: Zhou, Kaijian, et al.
Publicado: (2020)

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
por: Lei, Qingyang, et al.
Publicado: (2020)

Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy
por: Fan, Xiaona, et al.
Publicado: (2021)

Androgen Activity Is Associated With PD-L1 Downregulation in Thyroid Cancer
por: O’Connell, Timmy J., et al.
Publicado: (2021)

A miR-129-5P/ARID3A Negative Feedback Loop Modulates Diffuse Large B Cell Lymphoma Progression and Immune Evasion Through Regulating the PD-1/PD-L1 Checkpoint
por: Zheng, Weili, et al.
Publicado: (2021)

Universal cutoff for tumor mutational burden in predicting the efficacy of anti-PD-(L)1 therapy for advanced cancers
por: Mo, Shu-Fen, et al.
Publicado: (2023)

Identification of an Immune-Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of Urothelial Cancer
por: Li, Pengju, et al.
Publicado: (2021)

Dysregulation of miR-138-5p/RPS6KA1-AP2M1 Is Associated With Poor Prognosis in AML
por: Yu, Dong-Hu, et al.
Publicado: (2021)

Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1/PDL1 therapy
por: Luo, Kunpeng, et al.
Publicado: (2022)

Comprehensive Analysis of the Immune Infiltrates and PD-L1 of m(6)A RNA Methylation Regulators in Hepatocellular Carcinoma
por: Xu, Yangtao, et al.
Publicado: (2021)

MicroRNA-15a Carried by Mesenchymal Stem Cell-Derived Extracellular Vesicles Inhibits the Immune Evasion of Colorectal Cancer Cells by Regulating the KDM4B/HOXC4/PD-L1 Axis
por: Liu, Lei, et al.
Publicado: (2021)

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
por: Shi, Li, et al.
Publicado: (2013)

Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1
por: Mor, Adam, et al.
Publicado: (2022)

CARD-Associated Risk Score Features the Immune Landscape and Predicts the Responsiveness to Anti-PD-1 Therapy in IDH Wild-Type Gliomas
por: Li, Depei, et al.
Publicado: (2021)

Variant Profiling of a Large Cohort of 138 Chinese Families With Autosomal Dominant Retinitis Pigmentosa
por: Xiao, Ting, et al.
Publicado: (2021)

Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test
por: Yuan, Keyu, et al.
Publicado: (2022)

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
por: Jiang, Xianjie, et al.
Publicado: (2019)

Combined DNA Methylation and Transcriptomic Assessments to Determine a Prognostic Model for PD-1-Negative Hepatocellular Carcinoma
por: Zhu, Lixu, et al.
Publicado: (2021)

Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment
por: Wang, Rui-Bin, et al.
Publicado: (2020)

Effect of LncRNA-MALAT1 on mineralization of dental pulp cells in a high-glucose microenvironment
por: Li, Xinzhu, et al.
Publicado: (2022)

Overcoming of Radioresistance in Non-small Cell Lung Cancer by microRNA-320a Through HIF1α-Suppression Mediated Methylation of PTEN
por: Xu, Li-Ming, et al.
Publicado: (2020)

MicroRNA-155 Regulates MAIT1 and MAIT17 Cell Differentiation
por: Liu, Tingting, et al.
Publicado: (2021)

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
por: He, Jiabei, et al.
Publicado: (2015)

MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer
por: Yi, Ruibin, et al.
Publicado: (2022)

Iron-mediated oxidative stress induces PD-L1 expression via activation of c-Myc in lung adenocarcinoma
por: Battaglia, Anna Martina, et al.
Publicado: (2023)

Early Activation of Myeloid-Derived Suppressor Cells Participate in Sepsis-Induced Immune Suppression via PD-L1/PD-1 Axis
por: Ruan, Wei-Shuyi, et al.
Publicado: (2020)

PD-L1 Is a Tumor Suppressor in Aggressive Endometrial Cancer Cells and Its Expression Is Regulated by miR-216a and lncRNA MEG3
por: Xu, Daozhi, et al.
Publicado: (2020)

Immune Infiltrates of m(6)A RNA Methylation-Related lncRNAs and Identification of PD-L1 in Patients With Primary Head and Neck Squamous Cell Carcinoma
por: Feng, Zi-Yi, et al.
Publicado: (2021)

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
por: Wang, Man, et al.
Publicado: (2023)

Cell-in-Cell Phenomenon and Its Relationship With Tumor Microenvironment and Tumor Progression: A Review
por: Wang, Xinlong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_omtcllt379lsb4a92ub506ev9l